date,title,source
Oct-23-18,"IMV Inc. to Announce Third Quarter 2018 Financial Results and Host Earnings Call on November 2, 2018",GlobeNewswire
Nov-06-18,"Veteran Oncology Biotechnology Executive and Third Rock Ventures Entrepreneur in Residence Markus Warmuth, MD, Joins IMV Inc. Board of Directors",GlobeNewswire
Nov-15-18,IMV Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference,GlobeNewswire
Nov-16-18,"Recent Analysis Shows BioLineRx, Interlink Electronics, IMV INC, PAR Technology, Hudson Global, and Identiv Market Influences  Renewed Outlook, Key Drivers of Growth",GlobeNewswire
Nov-20-18,IMV Moves to Develop DPX-Survivac as Monotherapy for Recurrent Ovarian Cancer,GlobeNewswire
Nov-26-18,IMV Leadership to Present Respiratory Syncytial Virus (RSV) Research at RespiDART 2018,GlobeNewswire
Dec-10-18,IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivacs Phase 1b/2 Immunotherapy Combination Trial at the ESMO Immuno-Oncology Congress 2018,GlobeNewswire
Dec-13-18,IMV Inc. Presents Updated Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ESMO Immuno-Oncology Congress,GlobeNewswire
Jan-17-19,First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMVs DPX Delivery Platform in Ovarian Cancer Patients,GlobeNewswire
Jan-28-19,IMV to Present at 2019 BIO CEO & Investor Conference,GlobeNewswire
